Effect of One-Year Lumacaftor–ivacaftor Treatment on Glucose Tolerance Abnormalities in Cystic Fibrosis Patients

Journal of Cystic Fibrosis - Netherlands
doi 10.1016/j.jcf.2020.03.002
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cost Effectiveness of Ivacaftor and Lumacaftor Combination for the Treatment of Patients With Cystic Fibrosis in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Glucose Tolerance in Cystic Fibrosis.

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
1991English

Glucose Tolerance During Pulmonary Exacerbations in Children With Cystic Fibrosis

PLoS ONE
Multidisciplinary
2012English

Long-Term Computed Tomographic Changes in Cystic Fibrosis Patients Treated With Ivacaftor

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2016English

Lumacaftor/Ivacaftor Reduces Pulmonary Exacerbations in Patients Irrespective of Initial Changes in FEV1

Journal of Cystic Fibrosis
Child HealthPulmonaryPediatricsPerinatologyRespiratory Medicine
2019English

GP273 Corkambi: One Year Outcomes of Orkambi on Cystic Fibrosis Paediatric Patients in Cork University Hospital

2019English

Insulin Responses to Intravenous Glucose and the Hyperglycemic Clamp in Cystic Fibrosis Patients With Different Degrees of Glucose Tolerance

Pediatric Research
Child HealthPediatricsPerinatology
1994English

Bridging for Lung Transplantation With Lumacaftor/Ivacaftor

Breathe
PulmonaryRespiratory Medicine
2018English

Ivacaftor: A Novel Gene-Based Therapeutic Approach for Cystic Fibrosis

Journal of Pediatric Pharmacology and Therapeutics
Child HealthPediatricsPerinatologyPharmacology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy